These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12503818)

  • 1. Penetration of capecitabine and its metabolites into malignant and healthy tissue of patients with advanced breast cancer.
    Mader RM; Schrolnberger C; Rizovski B; Brunner M; Wenzel C; Locker G; Eichler HG; Mueller M; Steger GG
    Int J Clin Pharmacol Ther; 2002 Dec; 40(12):571-2. PubMed ID: 12503818
    [No Abstract]   [Full Text] [Related]  

  • 2. [Doxifluridine for treatment of colorectal cancer].
    Nishimura G; Miwa K
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():345-8. PubMed ID: 14574909
    [No Abstract]   [Full Text] [Related]  

  • 3. Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer.
    Mader RM; Schrolnberger C; Rizovski B; Brunner M; Wenzel C; Locker G; Eichler HG; Mueller M; Steger GG
    Br J Cancer; 2003 Mar; 88(5):782-7. PubMed ID: 12618890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic evaluation of capecitabine in breast cancer.
    Daniele G; Gallo M; Piccirillo MC; Giordano P; D'Alessio A; Del Giudice A; La Porta ML; Perrone F; Normanno N; De Luca A
    Expert Opin Drug Metab Toxicol; 2013 Feb; 9(2):225-35. PubMed ID: 23301520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo monitoring of capecitabine metabolism in human liver by 19fluorine magnetic resonance spectroscopy at 1.5 and 3 Tesla field strength.
    van Laarhoven HW; Klomp DW; Kamm YJ; Punt CJ; Heerschap A
    Cancer Res; 2003 Nov; 63(22):7609-12. PubMed ID: 14633676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tumor specific therapy. Targeted breast cancer therapy].
    MMW Fortschr Med; 2003 Sep; 145(38):62. PubMed ID: 14603691
    [No Abstract]   [Full Text] [Related]  

  • 7. Capecitabine in advanced gastric cancer.
    Okines A; Chau I; Cunningham D
    Expert Opin Pharmacother; 2007 Nov; 8(16):2851-61. PubMed ID: 17956204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer.
    Reigner B; Watanabe T; Schüller J; Lucraft H; Sasaki Y; Bridgewater J; Saeki T; McAleer J; Kuranami M; Poole C; Kimura M; Monkhouse J; Yorulmaz C; Weidekamm E; Grange S
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):193-201. PubMed ID: 12783206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine: in advanced gastric or oesophagogastric cancer.
    Dhillon S; Scott LJ
    Drugs; 2007; 67(4):601-10. PubMed ID: 17352519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine: effective oral fluoropyrimidine chemotherapy.
    McKendrick J; Coutsouvelis J
    Expert Opin Pharmacother; 2005 Jun; 6(7):1231-9. PubMed ID: 15957975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine: indications and future perspectives in the treatment of metastatic colorectal and breast cancer.
    Cassata A; Procoplo G; Alù M; Ferrari L; Ferrario E; Beretta E; Longarini R; Busto G; De Candis D; Bajetta E
    Tumori; 2001; 87(6):364-71. PubMed ID: 11989587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational development of capecitabine.
    Venturini M
    Eur J Cancer; 2002 Feb; 38 Suppl 2():3-9. PubMed ID: 11841929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capecitabine in colorectal, breast, and other solid tumors: novel therapeutic approaches. Selected abstracts from ASCO 2003.
    Oncology (Williston Park); 2003 Aug; 17(8 Suppl 8):10-62; quiz 63-4. PubMed ID: 14570064
    [No Abstract]   [Full Text] [Related]  

  • 14. [New therapeutic prospects with capecitabin in breast carcinoma].
    Venturini M; Catzeddu T
    Tumori; 2002; 88(1):A1-6. PubMed ID: 12008671
    [No Abstract]   [Full Text] [Related]  

  • 15. Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation.
    Tabata T; Katoh M; Tokudome S; Hosakawa M; Chiba K; Nakajima M; Yokoi T
    Drug Metab Dispos; 2004 Jul; 32(7):762-7. PubMed ID: 15205393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetic comparison of capecitabine and 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR)].
    Minami H; Ebi H
    Gan To Kagaku Ryoho; 2005 Dec; 32(13):2053-7. PubMed ID: 16352928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine in carcinoma of the pancreas.
    Smith DB; Neoptolemos JP
    Expert Opin Pharmacother; 2006 Aug; 7(12):1633-9. PubMed ID: 16872266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer.
    Wagstaff AJ; Ibbotson T; Goa KL
    Drugs; 2003; 63(2):217-36. PubMed ID: 12515569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU.
    Tsukamoto Y; Kato Y; Ura M; Horii I; Ishitsuka H; Kusuhara H; Sugiyama Y
    Pharm Res; 2001 Aug; 18(8):1190-202. PubMed ID: 11587492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function.
    Schüll B; Scheithauer W; Kornek GV
    Onkologie; 2003 Dec; 26(6):578-80. PubMed ID: 14709934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.